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Aims We investigated which patients with heart failure (HF) should receive specialist palliative care (SPC) by first creating
a definition of need for SPC in patients hospitalised with HF using patient-reported outcome measures (PROMs) and
then testing this definition using the outcome of days alive and out of hospital (DAOH). We also evaluated which
baseline variables predicted need for SPC and whether those with this need received SPC.
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Methods
and results
PROMs assessing quality of life (QoL), symptoms, and mood were administered at baseline and every 4months.
SPC need was defined as persistently severe impairment of any PROM without improvement (or severe impairment
immediately preceding death). We then tested whether need for SPC, so defined, was reflected in DAOH, a measure
which combines length of stay, days of hospital re-admission, and days lost due to death. Of 272 patients recruited,
74 (27%) met the definition of SPC needs. These patients lived one third fewer DAOH than those without SPC need
(and less than a quarter of QoL-adjusted DAOH). A Kansas City Cardiomyopathy Questionnaire (KCCQ) summary
score of <29 identified patients who subsequently had SPC needs (area under receiver operating characteristic curve
0.78). Twenty-four per cent of patients with SPC needs actually received SPC (n=18).
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Conclusions A quarter of patients hospitalised with HF had a need for SPC and were identified by a low KCCQ score on admission.
Those with SPC need spent many fewer DAOH and their DAOH were of significantly worse quality. Very few patients
with SPC needs accessed SPC services.
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Background
Patients with heart failure (HF) have a major symptom burden,
considerable impairment of quality of life (QoL) and high rates
of admission, re-admission and death.1,2 Palliative care (PC) is
defined by the World Health Organisation (WHO) as an approach
that improves the QoL of patients and their families facing a
life-threatening illness.3 It seems intuitive that some or even many
patients with HF would benefit from PC and several guidelines
advocate use of PC, alongside usual care, in selected patients
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. with HF.4,5 A recent policy statement goes further, recommending
that PC is integrated into the routine care of all patients with
advanced HF, with most needs managed by the usual care team.6
Those with more challenging PC needs should have access to
specialist PC (SPC) providers working in collaboration with the
usual-care team.6 While PC is a treatment which, in principle, can
be delivered by all health care professionals, SPC is provided by
multi-professional team who have undergone specialist training in
PC. SPC services often include access to additional resources such
as inpatient or outpatient hospice care. However, which patients
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should be selected is not clear and most clinicians do not find it
easy to identify those who should be referred to SPC services.7
This issue has been highlighted as requiring further research in the
European Society of Cardiology (ESC) Heart Failure Association
position statement on PC use in HF.8 Existing studies on this
subject have many limitations. For example, most enrolled highly
selected cohorts, did not follow patients over time (i.e. used
one-off assessments), or did not fully characterise the patients
studied (for example by recording the severity of HF or treatment
received).9
Therefore, our goal was to develop and to test a simple and prac-
tical definition of who needs SPC in a cohort of near-consecutive
patients admitted to hospital with worsening HF. We also com-
pared patients who actually received PC with those in need of SPC,
according to our definition.
Methods
Study patients and protocol
The design and rationale of this study are published.10 In a single
centre serving as a community hospital, near-consecutive patients
with suspected HF were screened for inclusion in the study between
9 January 2013 and 1 December 2014 (near-consecutive means
that patients were recruited consecutively except when the sin-
gle recruiting physician-investigator was on vacation). The ESC
guidelines were used to define HF.11 Patients were eligible for
inclusion if they had signs and symptoms of HF, a B-type natri-
uretic peptide (BNP) concentration>100 pg/mL, and objective
evidence of heart disease or dysfunction on echocardiography
(either left ventricular systolic dysfunction, elevated left ventric-
ular filling pressures, or significant valve disease). Patients were
excluded if they were unable or unwilling to provide written
informed consent.
During the index admission, medical and drug history, physical
examination, laboratory, and echocardiographic results were recorded.
A physician assessment of performance status was made using the
Australia modified Karnofsky Performance Status (AKPS) score, an
‘end-of-the-bed’ assessment ranging between 0–100, with lower
scores indicating lower performance status.12 A HF-specific assess-
ment of patients’ needs, using the Needs Assessment Tool-Progressive
Disease-Heart Failure (NAT-PD-HF), was also completed during index
admission,13 with patients deemed to have important needs if they
were assessed as having ‘significant concern’ on any of the NAT-PD-HF
patient wellbeing domains. Caregiver burden was assessed using the
Zarit Burden Interview (ZBI) questionnaire.14
Patient-reported outcome measures
Patients completed a variety of patient-reported outcome measures
(PROMs) chosen to quantify different potential PC needs includ-
ing QoL, symptom burden, and mood disturbance. Disease-related
QoL was assessed by the Kansas City Cardiomyopathy Question-
naire (KCCQ) and general QoL using the Short Form 12 (SF-12)
questionnaire.15,16 Symptom burden was assessed by the Edmonton
Symptom Assessment Scale (ESAS).17 Mood disturbance was assessed
using the Hospital Anxiety and Depression Scale (HADS).18 At every
study assessment all PROMs were repeated. PROMs were categorised



















































































.. HF (as well as definitions of severity where available) are described in
Table 1.15,16,18–21
Patients were reviewed every 4months (for a minimum of 8 and up
to a maximum of 28months). Study visits took place at the study centre
or in the patients’ own home, if they were too frail to attend the study
centre, or expressed a preference for this. Patients were also followed
up for a minimum of 12months and up to a maximum 21months
using electronic medical record linkage to document re-admission and
death. As described previously, the Scottish National Health Service
electronic medical record linkage enables follow-up for death (including
location) and hospitalisation (including cause).22 Electronic patient
records, PC registries, and hospice records were searched to identify
participants who accessed PC services.
The study team were not involved, nor did they influence the care of
patients. Patients admitted to hospital due to HF were treated as per
current guidelines.4 In our area usual practice is for patients to attend
follow-up clinic appointments with either a cardiologist or general
physician, as well as a general practitioner, and a HF liaison nurse. The
specific care patients received following discharge was not recorded as
part of this study.
The study protocol was approved by the local ethics committee and
the study was conducted according to the principles of the Declaration
of Helsinki. All participants provided written, informed consent. We
attest that we have obtained appropriate permissions and paid any
required fees for use of copyright protected materials.
Definition of need for specialist palliative
care
We defined need for SPC as severe impairment of any PROM persisting
for two or more consecutive study visits without improvement, or
severe impairment of any PROM followed by death before the PROM
was repeated, i.e. no improvement was reported in the PROM before
death (Figure 1). Patients who missed a study assessment were assumed
to have the same PROM score as previously recorded, that is, we
used last observation carried forward. There was no limit on how far
forward observations were carried.
Testing of definition of need for specialist
palliative care against days alive and out
of hospital (DAOH) and quality
of life-adjusted DAOH
Our definition of need for SPC was tested against DAOH,
QoL-adjusted, symptom-adjusted, and mood-adjusted DAOH. DAOH
is a measure that takes account of the length of the index hospitalisa-
tion, days of re-hospitalisation, and days of life lost due to death. For
example, a patient followed for a fixed period of 180 days with 10 days
of index hospitalisation, two further admissions of 10- and 15-day
duration, respectively, followed by death at day 135 would have 100
DAOH (out of a possible 180). To calculate QoL-adjusted DAOH,
the number of DAOH between each study assessment was calculated
(online supplementary Figure S1) and these days were then adjusted
according to the KCCQ overall summary score, to quality-weight
each DAOH. A higher KCCQ score equates to better QoL and
lower score to poorer QoL, with a range of 0–100. For example, if
a patient spent 100 DAOH and had a KCCQ summary score of 75
consistently over that period, this would be calculated as 100 x 0.75
QoL-adjusted DAOH, equating to 75 days of good health spent out
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Table 1 Patient-reported outcome measure severity cut-off definition
PROM Severity Cut-off Severity cut-off derivation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HADS Depression None/mild ≤10 Severity cut-off scores suggested by authors,
corroborated by normative data.18,20Moderate 11–15
Severe ≥16
HADS Anxiety None/mild ≤10 Severity cut-off scores suggested by authors,
corroborated by normative data.18,20Moderate 11–15
Severe ≥16
KCCQ summary score None/mild >50 Correlation of cut-offs with NYHA class, mortality,
and PC needs.15,19Moderate 25–50
Severe <25
ESAS summary score None/mild 0–33 Individual symptom score severity based on HF




None/mild >40.28 Severity scores based on normative data:
moderate= between 2–3 SD from mean;





None/mild >40.28 Severity scores based on normative data:
moderate= between 2-3 SD from mean;





Severely impaired Severe in any
PROM category
ESAS, Edmonton Symptom Assessment Scale; HADS, Hospital Anxiety and Depression Scale; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; NYHA,
New York Heart Association; PC, palliative care; PROM, patient-reported outcome measure; SD, standard deviation; SF-12, Short Form 12.
of hospital, or 25 of 100 days lost due to poor QoL. The proportion
of QoL-adjusted DAOH compared with the potential DAOH (all alive
and in full health, and without hospital admission) during the whole
study was calculated for each patient. No patient was excluded from
this analysis, as missing KCCQ scores were carried forward from the
previous study assessment. This analysis was then repeated, adjusting
DAOH for symptom burden using the ESAS summary score, HADS
summary score, and both the physical and mental summary QoL
scores of the SF-12, instead of KCCQ.
Statistical analysis
Continuous variables are expressed as median (interquartile range),
unless otherwise specified. Comparisons of categorical variables were
performed using Fisher’s exact test, and continuous variables were
compared using the Mann–Whitney U test. Multivariable logistic
regression was used to calculate odds ratios and 95% confidence
intervals for baseline variables associated with the need for SPC.
Baseline variables tested included common markers of prognosis,23
performance status assessment (using the AKPS),12 needs assess-
ment (using the NAT-PD-HF), and PROM summary scores. Cut-off
scores and area under the receiver operating characteristic curve
for continuous variables identified as predictors of SPC needs
were calculated using the Youden method.24 All statistical anal-
yses were performed using SAS® v9.2 (SAS Institute Inc., Cary,
NC, USA).
Results
A total of 829 near-consecutive patients with suspected HF were














































. 2014. Of these, 272 met the inclusion criteria and agreed to par-
ticipate in the study (online supplementary Figure S2). The median
time from admission to baseline assessment was 2 (Q1-Q3: 2–4)
days. Median length of stay was 9 (5–15) days. Median follow-up
via record-linkage was 775 (608–913) days. There were 103 (38%)
deaths during follow-up, four during the index hospital admission.
Overall, 217 (80%) patients were re-admitted to hospital during
follow-up (for any reason). In total, 963 individual patient assess-
ments were completed. Thirty-eight per cent of all study visits
were carried out in patients’ homes. A detailed description of the
proportion of patients attending each study assessment, including
the number of patients with missing data for each PROM at each
time point, is provided in the online supplementary Table S1. The
proportion of patients with missing PROM data at each study
assessment for reasons other than death, increased over time, from
19% at month 4 to 33% at month 24. No patients were lost to
follow-up for vital status.
PROMs at baseline
The findings for the individual PROMs at baseline are detailed in
Table 2. During the index hospitalisation, 114 (42%) patients had
severe impairment of at least one PROM (online supplementary
Table S2). More patients had a severely reduced KCCQ than a
severe score for any other PROM. Of the 114 patients who scored
severe in any PROM at baseline, 55 (48%) did so in two or more
PROMs. Patients in the group defined as needing SPC (see below)
had worse median summary scores and a higher proportion had a
severely impaired score for each PROM.
Symptom burden, assessed using the ESAS scale, was high
during the index admission (Figure 2), and patients with SPC
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Definition of specialist palliative care (SPC) needs: persistent impairment (≥2 consecutive assessments) of any patient-reported
outcome measure (PROM) without recovery, or severe impairment of any PROM without recovery preceding death. Patient 1 did not have
SPC needs as there was improvement of PROM(s) whereas there was persistent impairment without improvement in patient 3. Patient 4 has
SPC needs as there was severe impairment of PROM(s) preceding death, whereas patient 2 did not have severe impairment preceding death.
needs reported higher burden for each individual symptom, except
nausea (Figure 3).
PROMs during follow-up
The proportion of patients at each study assessment who scored
severe for each PROM, and the number of PROMs with a severe
scoring are shown in the online supplementary Table S2. Com-
pared with baseline, the percentage of patients who were classi-
fied as severe for any PROM reduced during follow-up, but ranged
between 26% and 36%. Of these patients, most had severe impair-
ment of disease-related QoL as assessed by the KCCQ, followed
by impairment of general QoL as assessed by the SF-12 Physical,
and then symptom burden as assessed by the ESAS.
Prevalence of specialist palliative care
needs
Of the 272 patients in this study, 74 (27%) had SPC needs using
the definition described in the Methods, i.e. persistently (≥2
consecutive study visits) severe impairment of any PROM without
improvement, or severe impairment of any PROM followed by
death before further PROMs could be recorded. Of the 74 patients
with SPC needs, 47 (64%) met our definition by having severe
impairment of at least one PROM preceding death and 46 (62%)
qualified by having persistently severe impairment of any PROM
without improvement (20 of 46 of the latter patients died during
follow-up).
Clinical characteristics of patients with a
need for specialist palliative care
The clinical characteristics of those with and without a need for
SPC are detailed in Table 3. Patients with a need for SPC had
a worse New York Heart Association (NYHA) class distribution
prior to admission, and a higher proportion of patients had been
























































.. to those without SPC needs. Physician assessed performance
status (using the AKPS) was lower (i.e. worse) in patients with
SPC needs and a higher proportion of those with SPC needs
were classified by a physician as having significant needs using
the NAT-PD-HF. Of the caregivers interviewed, 93 (34%) were
available and/or willing to complete the ZBI; for patients with
SPC needs, caregivers recorded worse overall scores and a higher
proportion of caregivers reported a moderate-to-severe burden
in the group defined as having a need for SPC, compared to those
without such a need.
A greater proportion of those who developed SPC needs
were men, although this difference was not statistically signifi-
cant (P= 0.076). Patients who developed SPC needs were also
younger (P= 0.041) and had a more frequent history of myocar-
dial infarction (P= 0.004) and diabetes (P= 0.029), but did not have
more total co-morbidity overall and did not have a significantly
higher BNP or lower estimated glomerular filtration rate (eGFR)
or haemoglobin (but did have a lower systolic blood pressure,
P= 0.018). A longer standing diagnosis of HF (>2 years) was no
more common in patients with a need for SPC, compared to those
without.
Testing the definition of need
for specialist palliative care–days spent
alive and out of hospital
Patients meeting our definition of needing SPC spent one third
fewer DAOH (not adjusted for QoL) than those without a need
for SPC; specifically, the median number of DAOH in patients with
a need for SPC was 402 (171–598) compared with 635 (419–802)
for those not meeting the definition of needing SPC (P< 0.001).
After adjusting each DAOH for symptom burden using the
ESAS, patients with SPC needs had under half the number of
symptom-adjusted DAOH as those who did not meet the definition
of SPC needs (Figure 4). Patients with SPC needs had a similar
reduction in QoL and mood-adjusted DAOH, using the mental and
physical components of the SF-12 and HADS, respectively. After
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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QoL assessment
KCCQ severity, n (%) <0.001
None/mild 6 (8) 54 (27)
Moderate 17 (23) 100 (51)
Severe 51 (69) 44 (22)
KCCQ summary score 16 (8–27) 39 (27–52) <0.001
SF-12 Physical severity, n (%) <0.001
None/mild 22 (31) 101 (57)
Moderate 34 (48) 57 (32)
Severe 15 (21) 20 (11)
SF-12 Physical summary
score
27 (21–31) 32 (25–38) <0.001
SF-12 Mental severity, n (%) <0.001
None/mild 45 (63) 154 (87)
Moderate 15 (21) 22 (12)
Severe 11 (16) 2 (1)
SF-12 Mental summary score 36 (26–44) 45 (37–53) <0.001
Symptom burden
assessment
ESAS severity, n (%) <0.001
None/mild 14 (19) 94 (48)
Moderate 45 (62) 90 (46)
Severe 14 (19) 12 (6)
ESAS summary score 53 (36–63) 34 (18–49) <0.001
Mood assessment
HADS Anxiety severity, n (%) <0.001
None/mild 38 (54) 158 (82)
Moderate 22 (31) 28 (15)
Severe 11 (16) 6 (3)
HADS Anxiety summary
score
10 (6–13) 6 (3–9) <0.001
HADS Depression severity, n
(%)
<0.001
None/mild 44 (61) 174 (89)
Moderate 24 (33) 15 (8)
Severe 4 (6) 6 (3)
HADS Depression summary
score
9 (7–12) 6 (3–9) <0.001
Values are expressed as median (interquartile range) unless otherwise stated.
ESAS, Edmonton Symptom Assessment Scale; HADS, Hospital Anxiety and Depression Scale;
KCCQ, Kansas City Cardiomyopathy Questionnaire; SPC, specialist palliative care; QoL,
quality of life; SF-12, Short Form 12.
adjusting each DAOH for impairment of QoL using the KCCQ,
patients with SPC needs enjoyed less than one quarter of the
number of QoL-adjusted DAOH of those without a need for SPC.
Prediction of which patients need
specialist palliative care
Results of the multivariable analysis of baseline prognostic mark-
ers using the MAGGIC (Meta-Analysis Global Group in Chronic
Heart Failure) risk model,25 performance status assessment, needs
assessment and PROMs are detailed in Table 4. The strongest pre-
dictor of developing a need for SPC was a low KCCQ score. The
optimal KCCQ cut-off for this purpose was a score of <29, giv-
ing a sensitivity and specificity of 80% and 71%, respectively, and
an area under the receiver operating characteristic curve of 0.78.



















































































.. impaired in our cohort (i.e. identifying a need for PC by our def-
inition), a sensitivity analysis was performed by omitting KCCQ
from the definition of PC needs (i.e. only using a persistently severe
impairment of the other PROMs/a severe impairment followed by
death before repeat assessment of the PROM). This resulted in
49 (18%) of patients meeting our definition of a need for PC. In
this sensitivity analysis using the full multivariable model, KCCQ
<29 remained the strongest and only significant predictor of SPC
(online supplementary Table S3).
Use of specialist palliative care services
Of the 272 patients studied, 32 (12%) accessed SPC services, either
as an inpatient or outpatient during follow-up. Of the 74 patients
who met our definition of SPC needs, 18 (24%) received SPC,
compared to 14 (7%) of the 198 patients who did not meet the
definition of SPC needs (P< 0.001). Five patients (7%) with a need
for SPC received hospice care, compared with one (0.5%) of those
without a need for SPC.
Discussion
Although it can be argued that all patients with HF should receive
PC, in that improvement in QoL is a treatment goal for everyone,
not all patients require SPC input. Physicians find it difficult to
identify which patients should be referred for SPC. We have
proposed and tested a definition of who will develop a need for
SPC and shown how this need can be identified before discharge
in patients hospitalised with worsening HF. Approximately one
quarter of a cohort of 272 nearly consecutively recruited patients
admitted to hospital with HF met this definition. Patients fulfilling
our definition had a greatly reduced number of DAOH (one third
fewer days than those without a need for SPC) and an even more
striking reduction in disease-related QoL-adjusted DAOH (one
quarter of those without a need for SPC). In investigating the
need for SPC, we used a broader range of quantifiable PROMs
than in any previous study and investigated a ‘real world’ group of
patients. We found that from among the PROMs used, the KCCQ
performed best and a score< 29 (out of 100) during admis-
sion was the strongest predictor of PC needs during follow-up.
By recruiting a near-consecutive cohort, we believe that our
results can be generalised to patients seen every day in clinical
practice.
Overall, the patients in our study were elderly, had multiple
co-morbidities, and most had a reduced ejection fraction, in
keeping with epidemiological studies and registries of patients
hospitalised with HF.26,27 Our definition of need for SPC iden-
tified a subset among these patients with characteristics that
intuitively make sense: they had worse prior NYHA class,
were more likely to have been recently hospitalised with HF
and had other, independent, measures of poor performance
(AKPS score) and needs (using the NAT-PD-HF), as well as
corroborating evidence of greater caregiver burden (ZBI).
Importantly, these patients were not clearly identified by tra-
ditional physiological markers of advanced HF such as low
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Edmonton Symptom Assessment Scale: symptom distribution at baseline.
Figure 3 Median symptom score in patients with and without
specialist palliative care (SPC) needs.
eGFR, or conventional prognostic markers such as ejection
fraction or BNP.
Patients with a need for SPC received similar treatment for
HF, compared to those without. This is an important additional
finding as most prior studies looking at potential SPC need in
patients with HF did not describe use of conventional HF ther-
apy. SPC, as an additional intervention, should mainly be consid-
ered in patients who continue to have a high symptom burden
and poor QoL despite use of evidence-based HF therapy.24 Pre-
scription of disease-modifying pharmacotherapy was high in our


















































.. few patients had a device (e.g. implantable cardioverter defibrilla-
tors, cardiac resynchronisation therapy, ventricular assist devices)
implanted.
We believe that our definition is intuitive and identifies patients
who have either poor QoL combined with greatly reduced life
expectancy or sustained and substantial impairment of QoL. It
accounts for the fluctuating nature of HF by using longitudinal
assessments. By using PROMs, the patient’s perspective of the
influence HF has on their lives is described, rather than taking the
physician’s perspective.
We have shown that the KCCQ summary score, assessed dur-
ing a hospital admission, can identify patients who had or go on
to develop a need for SPC. This measure was a more powerful
predictor of SPC need than variables usually considered predic-
tors of prognosis or variables reflecting performance status. Our
analysis shows that a KCCQ summary score of <29 is the best
tool, among a variety of PROMs, to identify those with a need
for SPC and this simple and reproducible PROM could easily be
adopted into clinical practice. One other study has also suggested
that the KCCQ might be useful for this purpose. In a retrospective
examination of the EVEREST (Efficacy of Vasopressin Antagonism in
Heart Failure Outcome Study with Tolvaptan) clinical trial, need for
SPC was arbitrarily defined as a KCCQ score persistently <45 or
death within 6months. In a multivariable analysis, a KCCQ score
of <25 was the strongest predictor of need for SPC defined in
this way.19 Although our study and the EVEREST analysis are com-
plementary, their design was quite different in that we enrolled a
near-consecutive and unselected cohort of patients with HF, tested
a variety of PROMs, conducted more frequent patient assessments
and tested our definition of need for SPC using a different out-
come. Nevertheless, the KCCQ emerged as the best PROM for
predicting those with a need for SPC. However, using a PROM for
this purpose is not possible for all patients admitted to hospital
with HF, as not every patient can complete a PROM, such as those
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Baseline clinical characteristics
SPC needs (n= 74) Not SPC needs (n= 198) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 73 (65–81) 77 (71–83) 0.041
Female sex 28 (38) 100 (51) 0.076
SBP, mmHg 127 (112–152) 136 (120–158) 0.018
BMI, kg/m2 28 (24–32) 26 (24–32) 0.245
NYHA class 0.031
II 20 (27) 62 (31)
III 33 (45) 108 (55)
IV 21 (28) 28 (14)
Medical history
Previous HF diagnosis 38 (51) 82 (41) 0.170
HF diagnosis >2 years 19 (26) 58 (29) 0.651
HF hospitalisation in preceding 6months 10 (14) 12 (6) 0.077
Hypertension 52 (70) 132 (67) 0.663
Myocardial infarction 41 (55) 70 (35) 0.004
Atrial fibrillation 41 (55) 103 (52) 0.683
TIA/CVA 11 (15) 41 (21) 0.385
Peripheral arterial disease 11 (15) 27 (14) 1.000
Diabetes 32 (43) 57 (29) 0.029
COPD 23 (31) 46 (23) 0.211
Depression 14 (19) 23 (12) 0.164
Cancer 7 (10) 24 (12) 0.670
ICD/CRT 5 (7) 13 (7) 1.000
Discharge medication
ACEi/ARB 48 (65) 137 (69) 0.559
Beta-blocker 48 (65) 144 (73) 0.232
MRA 24 (32) 67 (34) 0.886
Digoxin 20 (27) 56 (28) 0.880
Laboratory
BNP, pg/mL 807 (471–1810) 683 (417–1329) 0.192
Na+, mmol/L 138 (134–140) 138 (135–140) 0.621
eGFR, mL/min/1.73m2 55 (38–80) 63 (40–82) 0.639
Hb, g/L 120 (108–133) 123 (109–138) 0.346
Echocardiography
EF ≤50% 52 (70) 131 (66) 0.564
EF, % 36 (24–50) 40 (27–54) 0.191
LVIDD/BSA, mm/m2 30 (26–35) 29 (26–33) 0.397
Physician completed assessments
AKPS 60 (50–80) 80 (60–90) <0.001
NAT-PD-HF significant concern 28 (38) 42 (21) 0.008
Caregiver burden assessment
ZBI severity* <0.001
None/mild 9 (33) 48 (73)
Mild–moderate 12 (44) 13 (20)
Moderate–severe 6 (22) 5 (8)
ZBI summary score 24 (15–38) 12 (6–22) <0.001
Values are expressed as n (%) or median (interquartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AKPS, Australia modified Karnofsky Performance Status; BMI, body mass index; BSA, body
surface area; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronisation therapy; CVA, cerebral vascular accident; EF,
ejection fraction; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; HF, heart failure; ICD, implantable cardioverter defibrillator; LVIDD, left ventricular internal
diameter in diastole; MRA, mineralocorticoid receptor antagonist; Na+ , sodium; NAT-PD-HF, Needs Assessment Tool-Progressive Disease-Heart Failure; NYHA, New York
Heart Association; SBP, systolic blood pressure; SPC, specialist palliative care; TIA, transient ischaemic attack; ZBI, Zarit Burden Interview.
*93 caregivers completed the ZBI questionnaire at baseline.
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Figure 4 Quality of life-adjusted, symptom-adjusted, and mood-adjusted days alive and out of hospital (DAOH) analysis. ESAS, Edmonton
Symptom Assessment Scale; HADS, Hospital Anxiety and Depression Scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; SF12, Short
Form 12; SPC, specialist palliative care.
with cognitive impairment, or those with visual impairment or
reading difficulties.
The ability to identify patients with SPC needs is poten-
tially valuable from several perspectives. These individuals could
be the focus of efforts to improve QoL, attempts to prevent
re-admissions or interventions to improve quality of death, such
as those suggested in the ESC Heart Failure Association PC posi-
tion statement.8 A KCCQ score of <29 could also be used as
the main inclusion criterion for clinical trials aimed at testing SPC
interventions.
Despite over one quarter of patients meeting the definition of
need for SPC, very few patients accessed either SPC services or
hospice care; indeed, 74% of those with a SPC need did not access
these services. Perhaps because of uncertain criteria for who to
refer, few patients with HF receive SPC. Of all patients accessing
hospice care or SPC services in England and Wales in 2013–14,
88% had a diagnosis of cancer.28 In a recent audit of 54 654 patients
admitted to hospital with HF in England and Wales between
2013–14, only 4% were referred to SPC during admission.29
Two recent studies in the United States retrospectively analysed
large HF databases to identify patients thought likely to have SPC
needs.30,31 These studies identified 4474 and 32 270 patients,
respectively, thought to have SPC needs, of whom 7.6% and 9.6%
were seen by SPC services.
Study limitations
This study was conducted in a single secondary care centre which
potentially reduces the generalisability of the results. However,
this issue is mitigated by the benefit gained from reduction in













































.. unselected cohort. Another potential weakness of the study was
missed study assessments. These were unavoidable in a longitu-
dinal study assessing an elderly and co-morbid population. How-
ever, overall there were high study retention rates, due to the
high proportion of study assessments taking place in patients’
homes. No patients were lost to follow-up for vital status. The
overall proportion of missing PROM data, for reasons other
than death, was low, although we have made an assumption that
patients had the same PROM score at subsequent missed assess-
ments. This represents a potential weakness given the fluctuant
course of HF.
When calculating QoL-, mood-, and symptom-adjusted DAOH,
we have made an assumption that the patient had the same KCCQ,
SF-12, HADS, and ESAS score for each day until a subsequent
assessment was performed, i.e. last observation carried forward.
Although these PROMs were not designed or validated to provide
an assessment over 4months, we chose to use this frequency of
assessment to minimize patient study fatigue and to encourage
study retention.
To our knowledge there are no validated cut points for ‘mild’,
‘moderate’ and ‘severe’ grades of the ESAS summary score. Arbi-
trary points were therefore used, but this makes an assumption
that each symptom has the same weight in its effect on QoL. How-
ever, although this may not be the case, the findings are consistent
with the other measures of need.
Fourteen patients (7%) who did not meet our definition of
SPC need did access SPC services. This could potentially reflect a
weakness in the sensitivity of our definition of SPC need. However,
the individual reasons for referral to SPC were not available,
and given the co-morbid and elderly study patient population, it
is possible that some of these (and those with HF SPC needs)
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Table 4 Multivariable logistic regression of predictors
of specialist palliative care needs
Variable OR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MAGGIC risk score,
per 5 unit increase
1.03 (0.76–1.40) 0.861





























AKPS, Australia modified Karnofsky Performance Status; CI, confidence inter-
val; ESAS, Edmonton Symptom Assessment Scale; HADS, Hospital Anxiety and
Depression Scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; MAG-
GIC, Meta-Analysis Global Group in Chronic Heart Failure; NAT-PD-HF, Needs
Assessment Tool-Progressive Disease-Heart Failure; OR, odds ratio; SF-12,
Short Form 12.
accessed SPC services for another pathology such as cancer for
which the referral systems are much more robust.
Conclusion
We proposed and tested a definition in hospitalised HF patients
who subsequently need SPC; 27% of patients met this definition.
Patients who met this definition enjoyed only about a quarter of
the QoL-adjusted DAOH of those who did not. A KCCQ score of
<29 on admission identified patients who go on to have SPC needs
after discharge.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Completion of patient-reported outcome measures.
Table S2. Severity of PROM by study visit.
Table S3. Multivariable logistic regression of predictors of pallia-
tive care needs – sensitivity analysis –KCCQ removed from defi-



















































































.. Table S4. Multivariable logistic regression of predictors of pallia-
tive care needs best fit model using backwards selection.
Table S5. Multivariable logistic regression of predictors of
palliative care needs best fit model using backwards selec-
tion – sensitivity analysis – KCCQ removed from definition of
palliative care needs.
Figure S1. Calculation of days alive and out of hospital.
Figure S2. Screening and recruitment.
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